由LXR激活CTU2表达促进肝细胞癌的发展
Chao Xue1, Zhuo Wei2, Ye Zhang1
1College of Life Sciences, Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials of Ministry of Education, Nankai University, Tianjin, China.
Cell biology and toxicology
|April 17, 2024
概括
细胞体硫二酶2 (CTU2) 通过增强脂质生成促进肝细胞癌 (HCC). 抑制CTU2可以增强LXR连接体疗法,为HCC治疗提供了一种新的策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生化学
背景情况:
- 细胞系硫二酶2 (CTU2) 是一种参与tRNA修饰的酶,此前与乳腺癌和黑色素瘤有关.
- 它在肝细胞癌 (HCC) 进展中的作用在很大程度上仍未被探索.
研究的目的:
- 研究CTU2在HCC发育中的作用.
- 将CTU2定义为肝脏X受体 (LXR) 的基因.
- 探索CTU2在脂质生成中的机制及其在HCC中的治疗潜力.
主要方法:
- 使用HepG2细胞进行体外研究.
- 使用异种移植裸体小鼠模型进行体内研究.
- 对LXR反应元素的CTU2促进剂的分析和对LXR激活剂/淘汰效应的评估.
主要成果:
- 鉴定出CTU2表达受到LXR的调节,CTU2作为LXR基因.
- 发现CTU2通过促进脂质蛋白合成来增强脂质生成,这是脂质代谢中LXR的一种新机制.
- 减少CTU2表达导致瘤负担降低,并增强LXR配体的抗瘤作用,诱导细胞亡和抑制增殖.
结论:
- CTU2 是一个LXR标基因,通过脂质生成促进HCC的进展.
- 抑制CTU2可以增强HCC中LXR配体的抗瘤功效.
- CTU2代表了HCC治疗的有希望的治疗标,LXR激动剂提供了一种新的抗瘤策略.
更多相关视频
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
390
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
12.8K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K